Imatinib and dasatinib are well-known drugs for Philadelphia chromosome-positive chronic myeloid leukemia (CML) to inhibit the activity of Bcr-Abl, a tyrosine kinase of Bcr and Abl fusion protein. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.